A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a single arm, single center, open label pilot study of Orelabrutinib combined with
Rituximab, high-dose (HD) Methotrexate and Dexamethasone in newly-diagnosed primary central
nervous system lymphpoma (PCNSL). The purpose is to evaluate the safety and to find the
optimal dose of Orelabrutinib in this combination treatment for newly-diagnosed PCNSL
patients.